Micro
Aftermath
Active
Citi raises price target on MRK
Activity declining — narrative losing relevance.
Score
0.2
Velocity
▲ 0.0
Articles
14
Sources
2
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
Mar 28, 2026
RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium”
Neutral
Related Articles
Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates
Yahoo Finance
·
May 08, 2026
Jim Cramer Says “Merck Is Terrific”
Yahoo Finance
·
Apr 26, 2026
UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview
Yahoo Finance
·
Apr 19, 2026
TD Cowen Raises its Price Target on Marex Group plc (MRX) to $66 from $61
Yahoo Finance
·
Apr 04, 2026
RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium”
Yahoo Finance
·
Mar 28, 2026
Terns Pharmaceuticals Stock Gains 5% Over Acquisition Deal With Merck
Nasdaq
·
Mar 25, 2026
Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
Yahoo Finance
·
Mar 25, 2026
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Financial Services | +39.8% | |
| Healthcare | -3.9% | |
| Healthcare | +0.2% |
🤖
AI Overview
Citi raises price target on MRK
What happened: Citigroup analysts raised their price target on Merck & Co., Inc. (NYSE:MRK) to $145 from $130 on April 13, reiterating a 'Buy' rating. This follows Merck's Q1 earnings beat and positive analyst coverage, including inclusion in lists of top stocks to buy and high-dividend healthcare stocks. Additionally, Merck announced a partnership with Google Cloud and received bullish remarks from Jim Cramer.
Market impact: The pharmaceutical sector, particularly Merck, has seen increased investor interest. Merck's strong Q1 results, strategic partnerships, and analyst optimism have driven its stock price up. This positivity could spill over to other large-cap pharmaceutical companies with robust pipelines and dividend yields.
What to watch next: Merck's Q2 earnings report on July 28 and any updates on its pipeline, particularly Keytruda and Lynparza. Also, monitor Merck's progress in its Google Cloud partnership and any further analyst coverage or price target revisions.
What happened: Citigroup analysts raised their price target on Merck & Co., Inc. (NYSE:MRK) to $145 from $130 on April 13, reiterating a 'Buy' rating. This follows Merck's Q1 earnings beat and positive analyst coverage, including inclusion in lists of top stocks to buy and high-dividend healthcare stocks. Additionally, Merck announced a partnership with Google Cloud and received bullish remarks from Jim Cramer.
Market impact: The pharmaceutical sector, particularly Merck, has seen increased investor interest. Merck's strong Q1 results, strategic partnerships, and analyst optimism have driven its stock price up. This positivity could spill over to other large-cap pharmaceutical companies with robust pipelines and dividend yields.
What to watch next: Merck's Q2 earnings report on July 28 and any updates on its pipeline, particularly Keytruda and Lynparza. Also, monitor Merck's progress in its Google Cloud partnership and any further analyst coverage or price target revisions.
AI Overview as of May 10, 2026
Timeline
First SeenMar 25, 2026
Last UpdatedMar 25, 2026